𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low risk of alloimmunization to the D antigen in D− orthotopic liver transplant recipients receiving D+ RBCs perioperatively

✍ Scribed by Shan Yuan; Rebecca Davis; Qun Lu; Dennis Goldfinger; Alyssa F. Ziman

Book ID
109144324
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
90 KB
Volume
48
Category
Article
ISSN
0372-1248

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Increased incidence of cytomegalovirus i
Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis
✍ Kevin T. Shiley; Leanne B. Gasink; Todd D. Barton; Patrice Pfeiffenberger; Kim M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

Optimal measures for the prevention of cytomegalovirus (CMV) in high-risk orthotopic liver transplant (OLT) patients are unknown. The charts of high-risk OLT recipients with 12 months of follow-up who were transplanted over a 44-month period were reviewed. The incidence of CMV disease in CMV-seropos

Efficacy and safety of low-dose valganci
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
✍ Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d

A randomized, open-label study to evalua
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
✍ Gary L. Davis; David R. Nelson; Norah Terrault; Timothy L. Pruett; Thomas D. Sch 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Collaborative Antiviral Study Group Chronic hepatitis C is the most common indication for liver transplantation, but viral recurrence is universal and progressive graft injury occurs in most recipients. Our aim was to assess the safety, pharmacokinetics (PK), and antiviral effects of high doses

Evaluation of renal function in liver tr
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial
✍ Eric M. Yoshida; Paul J. Marotta; Paul D. Greig; Norman M. Kneteman; Denis Marle 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Posttransplant chronic renal failure, secondary to calcineurin inhibitor agents, is emerging as a major problem in liver transplantation. We report a randomized clinical trial comparing daclizumab, delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6), Investigational Arm (n

Hepatitis C virus–infected women have a
Hepatitis C virus–infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men
✍ Jennifer C. Lai; Elizabeth C. Verna; Robert S. Brown Jr.; Jacqueline G. O'Leary; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

In natural history studies of hepatitis C virus (HCV) infection, women have a lower risk of disease progression to cirrhosis. Whether female sex influences outcomes of HCV in the posttransplantation setting is unknown. All patients transplanted for HCV-related liver disease from 2002-2007 at five Un